|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,440,000 |
Market
Cap: |
2.04(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.46 - $3.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline consists of two compounds: seclidemstat (SP-2577), a small molecular inhibitor and SP-3164, a small molecular protein degrader. SP-2577 is a small-molecule lysine specific demethylase 1 (LSD1) inhibitor with a scaffold. LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth. SP-3164 is a cereblon binding molecular glue. SP-3164 degrades transcription factors IKZF1 and IKZF3, along with other proteins, resulting in both direct anti-cancer activity and immune-modulating properties. SP-3164 has activity in both hematologic and solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Arthur David J. |
Chief Executive Officer |
|
2022-03-03 |
4 |
B |
$0.39 |
$54,540 |
D/D |
139,488 |
249,674 |
2.81 |
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2021-11-03 |
4 |
A |
$0.72 |
$5,591 |
D/D |
7,787 |
34,073 |
|
- |
|
Arthur David J. |
Chief Executive Officer |
|
2021-11-03 |
4 |
A |
$0.72 |
$5,700 |
D/D |
7,939 |
110,186 |
|
- |
|
Arthur David J. |
Chief Executive Officer |
|
2021-08-17 |
4 |
B |
$0.89 |
$3,582 |
I/I |
4,000 |
102,247 |
2.58 |
- |
|
Hanish Arnold C |
Director |
|
2021-08-10 |
4 |
B |
$0.88 |
$6,167 |
I/I |
7,000 |
18,350 |
2.1 |
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2021-05-03 |
4 |
A |
$0.57 |
$5,422 |
D/D |
9,563 |
26,286 |
|
- |
|
Arthur David J. |
Chief Executive Officer |
|
2021-05-03 |
4 |
A |
$0.57 |
$5,569 |
D/D |
9,822 |
96,247 |
|
- |
|
Arthur David J. |
Chief Executive Officer |
|
2020-11-03 |
4 |
A |
$0.56 |
$2,737 |
D/D |
4,879 |
86,425 |
|
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2020-11-03 |
4 |
A |
$0.56 |
$2,650 |
D/D |
4,723 |
16,723 |
|
- |
|
Hanish Arnold C |
Director |
|
2020-08-21 |
4/A |
B |
$0.98 |
$3,920 |
I/I |
4,000 |
11,350 |
2.1 |
- |
|
Hanish Arnold C |
Director |
|
2020-08-21 |
4 |
B |
$0.98 |
$3,920 |
D/D |
4,000 |
11,350 |
2.31 |
- |
|
Arthur David J. |
Chief Executive Officer |
|
2020-08-19 |
4 |
B |
$1.01 |
$2,020 |
I/I |
2,000 |
2,000 |
2.58 |
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2020-08-17 |
4 |
B |
$1.00 |
$5,000 |
D/D |
5,000 |
12,000 |
2.74 |
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2020-02-19 |
4 |
B |
$0.95 |
$1,900 |
D/D |
2,000 |
7,000 |
2.66 |
- |
|
Jordan Scott |
Chief Business Officer |
|
2020-02-18 |
4 |
B |
$0.90 |
$10,170 |
D/D |
11,300 |
31,609 |
2.74 |
- |
|
Rosenblum Mark J |
Exec VP Finance, CFO |
|
2020-02-13 |
4 |
B |
$0.86 |
$4,295 |
D/D |
5,000 |
5,000 |
2.66 |
- |
|
Hanish Arnold C |
Director |
|
2020-02-11 |
4/A |
B |
$1.15 |
$5,003 |
I/I |
4,350 |
7,350 |
2.1 |
- |
|
Mcvicar William K. |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$10,005 |
D/D |
8,700 |
8,700 |
2.39 |
- |
|
Arthur David J. |
Chief Executive Officer |
|
2020-02-11 |
4 |
B |
$1.15 |
$2,501 |
D/D |
2,175 |
81,546 |
2.73 |
- |
|
Burleson Tess |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$5,003 |
D/D |
4,350 |
4,350 |
2.39 |
- |
|
Mccreedy Bruce J Jr. |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$10,005 |
D/D |
8,700 |
8,700 |
2.39 |
- |
|
Hanish Arnold C |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$5,003 |
D/D |
4,350 |
7,350 |
2.39 |
- |
|
Northrup Jonathan P |
Director |
|
2020-02-11 |
4 |
B |
$1.15 |
$10,005 |
D/D |
8,700 |
352,713 |
2.39 |
- |
|
Hanish Arnold C |
Director |
|
2019-11-25 |
4/A |
B |
$3.59 |
$10,770 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
Hanish Arnold C |
Director |
|
2019-11-25 |
4/A |
B |
$3.59 |
$10,770 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
156 Records found
|
|
Page 2 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|